ALK and non-small cell lung carcinoma: The crizotinib Ctrough,ss for these 13 patients (median, 434 ng/mL; range, 326–734 ng/mL) appeared to be above the median Ctrough,ss obtained in a population of 801 crizotinib-treated patients with ALK-positive NSCLC from PROFILE 1005 and PROFILE 1007 for whom crizotinib plasma concentrations were available (307 ng/mL).